AGTC Applied Genetic Technologies Corp

Price (delayed)

$0.617

Market cap

$31.3M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.4

Enterprise value

-$11.99M

Applied Genetic Technologies Corp. (AGTC) is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a ...

Highlights
Applied Genetic Technologies's EPS has increased by 35% YoY and by 4.8% QoQ
AGTC's debt has soared by 68% YoY
The quick ratio has plunged by 61% YoY and by 13% from the previous quarter

Key stats

What are the main financial stats of AGTC
Market
Shares outstanding
50.73M
Market cap
$31.3M
Enterprise value
-$11.99M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.56
Price to sales (P/S)
53.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-23.97
Earnings
Revenue
$500,000
EBIT
-$62.34M
EBITDA
-$60.39M
Free cash flow
-$62.3M
Per share
EPS
-$1.4
Free cash flow per share
-$1.43
Book value per share
$1.1
Revenue per share
$0.01
TBVPS
$1.97
Balance sheet
Total assets
$87.19M
Total liabilities
$40.16M
Debt
$24.56M
Equity
$47.03M
Working capital
$44.72M
Liquidity
Debt to equity
0.52
Current ratio
2.73
Quick ratio
2.63
Net debt/EBITDA
0.72
Margins
EBITDA margin
-12,078.6%
Gross margin
100%
Net margin
-12,538.6%
Operating margin
-12,447.4%
Efficiency
Return on assets
-60.1%
Return on equity
-98.8%
Return on invested capital
-303.4%
Return on capital employed
-101.6%
Return on sales
-12,468.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AGTC stock price

How has the Applied Genetic Technologies stock price performed over time
Intraday
-25.13%
1 week
-21.9%
1 month
-26.53%
1 year
-85.72%
YTD
-67.53%
QTD
-42.34%

Financial performance

How have Applied Genetic Technologies's revenue and profit performed over time
Revenue
$500,000
Gross profit
$500,000
Operating income
-$62.24M
Net income
-$62.69M
Gross margin
100%
Net margin
-12,538.6%
Applied Genetic Technologies's operating income has decreased by 5% YoY
AGTC's net income is down by 4.1% year-on-year

Growth

What is Applied Genetic Technologies's growth rate over time

Valuation

What is Applied Genetic Technologies stock price valuation
P/E
N/A
P/B
0.56
P/S
53.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-23.97
Applied Genetic Technologies's EPS has increased by 35% YoY and by 4.8% QoQ
The stock's price to book (P/B) is 65% less than its last 4 quarters average of 1.6 and 57% less than its 5-year quarterly average of 1.3
Applied Genetic Technologies's equity has plunged by 52% YoY and by 9% from the previous quarter
AGTC's price to sales (P/S) is 72% lower than its last 4 quarters average of 192.6 but 5% higher than its 5-year quarterly average of 51.2

Efficiency

How efficient is Applied Genetic Technologies business performance
AGTC's ROIC has shrunk by 165% YoY and by 23% QoQ
AGTC's ROE is down by 19% from the previous quarter and by 9% YoY
AGTC's return on assets is down by 9% since the previous quarter but it is up by 3.2% year-on-year

Dividends

What is AGTC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AGTC.

Financial health

How did Applied Genetic Technologies financials performed over time
AGTC's total assets is 117% higher than its total liabilities
The quick ratio has plunged by 61% YoY and by 13% from the previous quarter
The company's current ratio has shrunk by 60% YoY and by 13% QoQ
AGTC's debt is 48% less than its equity
AGTC's debt has soared by 68% YoY
Applied Genetic Technologies's equity has plunged by 52% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.